FindTrial
Sign In

Clinical study of interferon - alpha preemptive therapy after allogeneic hematopoietic stem cell transplantation

Clinical study of interferon - alpha preemptive therapy after allogeneic hematopoietic stem cell transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031048
Enrollment
Unknown
Registered
2020-03-21
Start date
2020-03-16
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute leukemia

Interventions

Case series:Interferon alpha

Sponsors

Beijing University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. With acute leukemia; 2. 2-65 years old; 3. Patients in complete remission stage before transplantation and positive for minimal residual disease after transplantation; 4. Patients requiring IFN-alpha preemptive treatment.

Exclusion criteria

Exclusion criteria: 1. active GVHD; 2. With active infection; 3. Patients with Myelosuppression; 4. With organ failure; 5. Patients who refuse to receive interferon alpha.

Design outcomes

Primary

MeasureTime frame
Relapse;—

Secondary

MeasureTime frame
Disease-free survival;Overall survival;Non-relapse mortality;Molecular response;—

Countries

China

Contacts

Public ContactMo Xiaodong

Beijing University People's Hospital

mxd453@163.com+86 10 88326001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026